Alzheimer's Tau Platform: Regimen A - AADvac1
This study, called Regimen A, is part of a larger research program looking into new treatments for Alzheimer's disease. It's testing a drug called AADvac1, either by itself or together with another drug called donanemab. Donanemab will also be given alone as a comparison. The goal is to see if these treatments can reduce tau protein buildup in the brain, which is a sign of Alzheimer's. You might be able to join if you are between 50 and 80 years old and have early signs of Alzheimer's or are at risk for it. The study plans to enroll 450 people. Success will be measured by how much tau protein in the brain changes over 30 months, as seen on special brain scans (PET scans). The current status of this specific study is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It's part of a larger "platform" trial where different treatments can be tested at the same time or one after another. Participants will be randomly assigned to receive AADvac1 alone, AADvac1 with donanemab, or donanemab alone.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main goal of the study will be measured over 30 months, suggesting participants will be followed for at least that long.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Alzheimer's Tau Platform: Regimen A - AADvac1
At a glance
Conditions
NCT07167966
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Butler Hospital Memory and Aging Program
Providence, Rhode Islandno site contact published
University of California, San Francisco (UCSF), Memory and Aging Center
San Francisco, Californiano site contact published
Vanderbilt University Medical Center
Nashville, Tennesseeno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Adam Boxer, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco (UCSF), Memory and Aging Center
- Keith Johnson, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital (MGH), Harvard Medical School
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Reduction of brain tau deposition as measured by tau positron emission tomography (PET)0, 6, 18 and 30 months
To determine whether at least one tau therapy, either alone or in combination with donanemab, will produce a greater reduction in brain tau deposition as measured by 18F-MK-6240 PET compared to donanemab alone.